secwatch.observer — SEC 8-K summary
======================================

Issuer:     Immunovant, Inc. (IMVT)
CIK:        0001764013
Form:       8-K
Filed at:   2022-09-28T23:59:59+00:00
Accession:  0001764013-22-000118
Event type: other_material
Sentiment:  positive
Materiality: 0.80
Item codes: 7.01, 8.01, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Immunovant announces next-generation anti-FcRn IMVT-1402 with promising preclinical data
--------------------------------------------------------------------------------

- IMVT-1402 showed deep IgG lowering with minimal impact on albumin and LDL in animal studies.
- Plan to submit IND and initiate Phase 1 study in early 2023 with initial data expected in mid-2023.
- Cash runway guidance into calendar year 2025 remains unchanged, including Phase 1 costs for IMVT-1402.
- Composition of matter patent protection expected for IMVT-1402 through at least 2042.
- Batoclimab programs in Myasthenia Gravis, Thyroid Eye Disease, CIDP and Graves' Disease continue at full speed.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1764013/000176401322000118/0001764013-22-000118-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1764013/000176401322000118/imvt-20220928.htm
  HTML page:      https://secwatch.observer/filing/0001764013-22-000118

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer